Insys Therapeutics (INSY) Misses Q3 EPS

Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of ($0.41), $0.20 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $23.52 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c